Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) agreed to engage China Resources Kelun as a downstream distributor and seller for some of its commercialized products from time to time during Oct. 31, 2024, and Dec. 31, 2025, a Thursday Hong Kong bourse filing said.
Under the agreement, the company will sell its commercialized products to the other party from time to time, which the other party will distribute downstream or sell directly to the consumers.
The annual caps set for the transactions are 10 million yuan for 2024 and 15 million yuan for 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments